Skip to main content

Table 1 Baseline characteristics of patients with and without diabetes (medical history of diabetes or concomitant use of antidiabetic treatment) across three phase III studies

From: Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials

 

With diabetes (N = 184)

Without diabetes (N = 1928)

p value

Age (years)

  

< 0.0001

 Mean (SD)

56.5 (9.4)

51.0 (12.1)

 

Sex, n (%)

  

0.3348

 Female

146 (79.3)

1585 (82.2)

 

 Male

38 (20.7)

343 (17.8)

 

Race, n (%)

  

0.0907

 Caucasian/White

147 (79.9)

1607 (83.4)

 

 Black

8 (4.3)

44 (2.3)

 

 Asian

15 (8.2)

99 (5.1)

 

 Other

14 (7.6)

178 (9.2)

 

Weight (kg)

  

< 0.0001

 Mean (SD)

84.08 (21.59)

74.04 (18.76)

 

Body mass index (kg/m2)

  

< 0.0001

 Mean (SD)

32.18 (7.40)

28.04 (6.38)

 

Duration of RA since diagnosis (years)

  

0.6294

 Mean (SD)

9.82 (8.81)

9.51 (8.44)

 

Rheumatoid factor, n (%)

  

0.0964

 Positive

136 (74.3)

1517 (79.5)

 

 Negative

47 (25.7)

390 (20.5)

 

Anti CCP antibody, n (%)

  

0.0593

 Positive

143 (77.7)

1587 (83.2)

 

 Negative

41 (22.3)

320 (16.8)

 

Tender joint count (0–68)

  

0.0017

 Mean (SD)

30.97 (15.92)

27.11 (14.11)

 

Swollen joint count (0–66)

  

0.0185

 Mean (SD)

19.72 (11.90)

17.57 (10.02)

 

HAQ-DI (0–3)

  

0.0010

 Mean (SD)

1.82 (0.66)

1.66 (0.63)

 

CRP (mg/L)

  

0.3210

 Mean (SD)

24.90 (29.39)

22.67 (24.22)

 

Oral glucocorticosteroid use, n (%)

119 (64.7)

1177 (61.0)

0.3344

 Mean (SD) prednisone equivalent dose, mg

6.6 (2.63)

6.6 (2.68)

0.7462

Hydroxychloroquine use, n (%)

4 (2.2)

33 (1.7)

> 0.9999

Antidiabetic medication use, n (%)

143 (77.7)

NR

NR

 Any noninsulin blood glucose-lowering drug, n (%)a

85 (46.2)

NR

NR

 ≥ 2 noninsulin blood glucose-lowering drugs, n (%)b

32 (17.4)

NR

NR

 Any insulin and analogue without oral blood glucose lowering drug, n (%)

13 (7.1)

NR

NR

 Any insulin and analogue plus oral blood glucose lowering drug, n (%)

14 (7.6)

NR

NR

  1. Percentages are calculated using number of patients assessed as denominator
  2. p values are based on t test for continuous variables and chi-square test if frequency in all cells ≥ 5 and Fisher exact test if frequency in at least one cell < 5, for categorical variables
  3. CCP cyclic citrullinated peptide, CRP C-reactive protein, HAQ-DI Health Assessment Questionnaire-Disability Index, Number number of patients assessed, NR not relevant, RA rheumatoid arthritis, SD standard deviation
  4. aExcluding insulins, monotherapy
  5. bExcluding insulins